Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NRX Pharmaceuticals (NRXP) Research & Development (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Research & Development for 2 consecutive years, with $558000.0 as the latest value for Q4 2025.

  • Quarterly Research & Development fell 46.14% to $558000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, down 35.31% year-over-year, with the annual reading at $3.8 million for FY2025, 39.07% down from the prior year.
  • Research & Development for Q4 2025 was $558000.0 at NRX Pharmaceuticals, down from $1.4 million in the prior quarter.
  • The five-year high for Research & Development was $2.8 million in Q2 2024, with the low at $558000.0 in Q4 2025.